Evommune CFO buys 1,000 shares in open market

Evommune, Inc. Chief Financial Officer Kyle Carver purchased 1,000 shares of common stock in an open-market transaction at $13.26 per share, bringing his direct holdings to 60,335 shares.

Rhea-AI Filing Summary

Evommune, Inc. Chief Financial Officer Kyle Carver purchased 1,000 shares of common stock in an open-market transaction at $13.26 per share, bringing his direct holdings to 60,335 shares. A prior sale of 1,000 shares at $23.42 on May 28, 2026 triggered Section 16(b) short-swing profit rules, and he agreed to pay $10,160 of profit to Evommune.

Insider Trade Summary

Net Buyer: 1,000 shares

Net Buy 1 txn

Insider Carver Kyle

Role Chief Financial Officer

Bought 1,000 shs ($13K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	1,000	$13.26	$13K

Holdings After Transaction: Common Stock — 60,335 shares (Direct)

Footnotes (1)

1. F1. The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.

Key Figures

Shares purchased: 1,000 shares Purchase price: $13.26 per share Shares held after transaction: 60,335 shares +2 more

5 metrics

Shares purchased 1,000 shares Open-market purchase of common stock on July 8, 2026

Purchase price $13.26 per share Price paid for 1,000 Evommune common shares

Shares held after transaction 60,335 shares Direct holdings of CFO Kyle Carver following the purchase

Prior sale price $23.42 per share Price for 1,000 shares sold on May 28, 2026, matched under Section 16(b)

Short-swing profit remitted $10,160 Amount the reporting person agreed to pay to Evommune

Key Terms

Section 16(b), short-swing transaction, open-market purchase

3 terms

Section 16(b) regulatory

"matchable under Section 16(b) of the Securities Exchange Act of 1934"

A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.

short-swing transaction regulatory

"profit realized in connection with the short-swing transaction"

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Evommune (EVMN) report for CFO Kyle Carver?

Evommune reported that CFO Kyle Carver bought 1,000 shares of common stock in the open market at $13.26 per share, increasing his direct ownership to 60,335 shares.

At what price did the Evommune (EVMN) CFO buy shares on July 8, 2026?

On July 8, 2026, Evommune’s CFO Kyle Carver purchased 1,000 shares of common stock at a price of $13.26 per share in an open-market transaction.

How many Evommune (EVMN) shares does CFO Kyle Carver hold after the reported trade?

After the reported purchase, CFO Kyle Carver directly holds 60,335 shares of Evommune common stock, according to the Form 4 ownership information provided.

What earlier Evommune (EVMN) stock sale was matched under Section 16(b)?

The filing notes a prior sale by CFO Kyle Carver of 1,000 shares of Evommune common stock at $23.42 per share on May 28, 2026, which was matchable under Section 16(b).

How much short-swing profit will be paid back to Evommune (EVMN) under Section 16(b)?

The reporting person agreed to pay Evommune $10,160, representing the full profit realized from the Section 16(b) short-swing transaction involving the matched purchase and sale of 1,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carver Kyle

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		P(1)		1,000	A	$13.26	60,335	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)